TBX3NCT00581152
The Role of TBX3 in Human ES Cell Differentiation
An observational study of TBX3 and Cell Differentiation, run by University of California, Irvine.
Trial summary
Stem cells can develop into every cell, every tissue and every organ in the human body, e.g., they can make any kind of cells in the human body. Stem cells reproduce themselves many times over and over. Their almost limitless potential has made stem cells a significant focus of medical research. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- TBX3, Cell Differentiation
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Aug 2007to 28 Aug 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: No subjects will be consented for this study. Approximately 2 to 4 cell lines will be collected.
Who may be able to join
- none
Who cannot join
- none
About this study
Stem cells can develop into every cell, every tissue and every organ in the human body, e.g., they can make any kind of cells in the human body. Stem cells reproduce themselves many times over and over. Their almost limitless potential has made stem cells a significant focus of medical research. But before scientists can use stem cells for medical purposes, they must first learn how to harness their power. They cannot treat disease until they learn how to manipulate stem cells to get them to develop into specific tissues or organs.
We know that turning genes on and off is crucial to the process differentiation, so we can add some factor into the culture dish and observe stem cells to differentiate into specific types of cells. But some sort of signal is needed to actually trigger the stem cells to differentiate. We are still searching for that signal. If we can ultimately learn how to direct stem cells to differentiate into one type of tissue or another, then we can use them to treat patients. In this proposal, we will first examine this step.
We propose a novel approach to understanding differentiation of human embryo stem (hES) cells, by studying TBX3, a protein called a transcription factor that controls the expression of other genes. In humans, the loss of function of TBX3 causes Ulnar-Mammary Syndrome, a genetic disorder that can pass from one generation to the next. Furthermore, our preliminary results show that TBX3 is downstream mediator of another protein, BMP4. BMP4 is a known key regulator for hES cell differentiation. Thus, TBX3 is an attractive candidate as a downstream mediator of BMP4 in hES cell differentiation. We will test TBX3 effects on hES cell differentiation if down-regulate TBX3 in hES cells with a technology called siRNA knockdown. We will identify the genes controlled by TBX3 with a recently invented powerful technology called CHIP-GLAS. This technique allows us to examine thousands of genes on a small chip in a single experiment. We expect that the innovative experiments proposed here will open a new avenue to understanding the signal of hES cell differentiation.
Read the detailed description
PURPOSE OF STUDY The purpose of this study is to understand what triggers stem cells to differentiate into one type of tissue or another. The study of TBX3, a protein called a transcription factor that controls the expression of other genes, shows that it is a downstream mediator of the protein BMP4, a known key regulator for hES cell differentiation.
Hypothesis and Aims
To understand the role of TBX3 in hES cell differentiation, we hypothesize that TBX3 is a downstream mediator of BMP4 and play an important role in hES cell differentiation. We propose the following specific aims:
- To examine TBX3 function in hES cell differentiation. NIH approved hES cells will be cultured in a conditioned medium with BMP4 to induce differentiation and TBX3 expression. TBX3 will be knocked down with siRNA technology. The cell morphology and biochemical changes will be examined for the effects of TBX3 knockdown on hES cell differentiation, including testing human ß-CG estradiol and progesterone. The gene expression profile will also be examined with Affymetrix gene expression chip and verified with real-time RT-PCR.
- To identify the genome-wide downstream targets directly bound by TBX3 in hESC with Chromatin immunoprecipitation-guided ligation and selection (CHIP-GLAS). To identify the targets of TBX3 in BMP4-induced hES cells, we will perform ChIP-GLAS analysis. CHIP-GLAS is a novel high-throughput technique with combination of chromatin precipitation and oligonucleotide-based microarray. This technology will allow us to identify the genome-wide downstream target genes directly bound by TBX3 in hES cells.
We expect that the proposed experiments will identify a key regulator for hES cell differentiation and open a new avenue to understanding the function of TBX3 in hES cells. The CHIP-GLAS promoter array provides us a cutting edge tool and allows us to examine the broad function of TBX3. We anticipate that the study will significantly enhance our understanding of TBX3 function in hES cell differentiation.
STUDY DESIGN NIH-approved cell lines will be available at the Sue and Bill Gross Stem Cell Research Core Facility at the University of California, Irvine. Non-NIH-approved cell lines will be obtained from Sue \& Bill Gross Stem Cell Core at UC Irvine.
Environment: Huang Lab is currently supported by the Helen and Larry Hoag Foundation and the Susan Komen Foundation. There are no active grants from the federal government. Previously, Dr. Huang was supported by K23 and R03 grants. They were completed in 2004 and 2006, respectively. No equipment was purchased with the funds from the federal grants. As all equipment currently in Huang lab was purchased with the UCI startup fund or with private funds, there is no conflict with government regulations.
At University California, Irvine, Sue and Bill Gross Stem Cell Research Center will be a key component of the Stem Cell Core Facility. This facility provides stem cell technology and resources to the UCI faculty (Please see attached letter). By merging technical and scientific expertise in a number of essential disciplines, the Core harbors a diverse tool kit for the exploration of multiple aspects of stem cell biology. The Core also provides a knowledge base for differentiating, genetically modifying and assaying human embryonic stem cells (hESCs) in support of multiple stem cell projects on campus and in the surrounding area. All services and procedures are performed in accordance with good quality assurance and record keeping practices pursuant to standard operating procedures and good laboratory practices.
The Sue and Bill Gross Stem Cell Research Center The human embryonic stem (hES) cell core facility of the Sue and Bill Gross Stem Cell Research Center opened in April 2006. It occupies approximately 10,000 square feet of space in the research park immediately adjacent to the University of California, Irvine campus. Approximately $1.7 million were committed by the UCI to fully equip the facility for all aspects on hES cell research. Further gifts totaling $236,687 from the Fuji Foundation and the Nichols Foundation provided additional major equipment and supplies that are available for all investigators. The facility was set up as a Federal-free zone in which investigators can to carry out all aspects of hES cell research. Individual rooms are equipped with tissue culture biosafety cabinets, CO2 incubators, an inverted microscope, a dissecting microscope, digital imaging equipment, a centrifuge, a water bath and a dedicated refrigerator and freezer. Ten such tissue culture set-ups as well as standard lab bench space are available to UCI investigators and visitors.
The facility also has major pieces of equipment needed for hES cell analysis such as a Zeiss 510 Meta Two-Photon Confocal Microscope. The facility will shortly have a BD LSR II Flow cytometer and a BD FacsAria cell sorter. Pretested reagents will be available to investigators through the core facility. These will include medium components, growth factors, feeder cells, gelatin, Matrigel, antibodies and primers to assay stem cell marker expression. In addition, the core facility will assist in karyotype analysis and tumor formation tests of hES cells.
- Conditions
- TBX3, Cell Differentiation
- Keywords
- TBX3
What is being measured
The primary outcome is the main question the study is designed to answer.
The cell morphology and biochemical changes will be examined for the effects of TBX3 knockdown on hES cell differentiation, including testing human ß-CG estradiol and progesterone.
Measured: 3 years
To identify the targets of TBX3 in BMP4-induced hES cells, we will perform ChIP-GLAS analysis. CHIP-GLAS will allow us to identify the genome-wide downstream target genes directly bound by TBX3 in hES cells.
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2007 (estimated)
- Study startAug 2007
- Primary completion28 Aug 2010
- Study completion28 Aug 2010
Why it stopped: IRB suspension
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TBX3Studies of the same condition, open and under way.
- More trials run by University of California, IrvineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Irvine
- Sponsor type
- University, hospital or other
- Collaborators
- CIRM SEED Grant
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00581152
- Sponsor's protocol ID
- OCRT07015 [HS# 2007-5848]
- Other IDs
- HS# 2007-5848
- Status last verified
- Jan 2021
- First submitted
- 18 Dec 2007
- Last updated
- 25 Jan 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of TBX3 in Human ES Cell Differentiation
- ClinicalTrials.gov ID
- NCT00581152
- Acronym / sponsor ID
- OCRT07015 [HS# 2007-5848]
- Conditions
- TBX3, Cell Differentiation
- Keywords
- TBX3
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: IRB suspension
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of California, IrvineUniversity, hospital or other
- Collaborators
- CIRM SEED Grant
- Study start
- Aug 2007
- Primary completion
- 28 Aug 2010 (actual)
- Study completion
- 28 Aug 2010 (actual)
- First posted
- 27 Dec 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Stem cells can develop into every cell, every tissue and every organ in the human body, e.g., they can make any kind of cells in the human body. Stem cells reproduce themselves many times over and over. Their almost limitless potential has made stem cells a significant focus of medical research. But before scientists can use stem cells for medical purposes, they must first learn how to harness their power. They cannot treat disease until they learn how to manipulate stem cells to get them to develop into specific tissues or organs.
We know that turning genes on and off is crucial to the process differentiation, so we can add some factor into the culture dish and observe stem cells to differentiate into specific types of cells. But some sort of signal is needed to actually trigger the stem cells to differentiate. We are still searching for that signal. If we can ultimately learn how to direct stem cells to differentiate into one type of tissue or another, then we can use them to treat patients. In this proposal, we will first examine this step.
We propose a novel approach to understanding differentiation of human embryo stem (hES) cells, by studying TBX3, a protein called a transcription factor that controls the expression of other genes. In humans, the loss of function of TBX3 causes Ulnar-Mammary Syndrome, a genetic disorder that can pass from one generation to the next. Furthermore, our preliminary results show that TBX3 is downstream mediator of another protein, BMP4. BMP4 is a known key regulator for hES cell differentiation. Thus, TBX3 is an attractive candidate as a downstream mediator of BMP4 in hES cell differentiation. We will test TBX3 effects on hES cell differentiation if down-regulate TBX3 in hES cells with a technology called siRNA knockdown. We will identify the genes controlled by TBX3 with a recently invented powerful technology called CHIP-GLAS. This technique allows us to examine thousands of genes on a small chip in a single experiment. We expect that the innovative experiments proposed here will open a new avenue to understanding the signal of hES cell differentiation.
Detailed description
PURPOSE OF STUDY The purpose of this study is to understand what triggers stem cells to differentiate into one type of tissue or another. The study of TBX3, a protein called a transcription factor that controls the expression of other genes, shows that it is a downstream mediator of the protein BMP4, a known key regulator for hES cell differentiation.
Hypothesis and Aims
To understand the role of TBX3 in hES cell differentiation, we hypothesize that TBX3 is a downstream mediator of BMP4 and play an important role in hES cell differentiation. We propose the following specific aims:
- To examine TBX3 function in hES cell differentiation. NIH approved hES cells will be cultured in a conditioned medium with BMP4 to induce differentiation and TBX3 expression. TBX3 will be knocked down with siRNA technology. The cell morphology and biochemical changes will be examined for the effects of TBX3 knockdown on hES cell differentiation, including testing human ß-CG estradiol and progesterone. The gene expression profile will also be examined with Affymetrix gene expression chip and verified with real-time RT-PCR.
- To identify the genome-wide downstream targets directly bound by TBX3 in hESC with Chromatin immunoprecipitation-guided ligation and selection (CHIP-GLAS). To identify the targets of TBX3 in BMP4-induced hES cells, we will perform ChIP-GLAS analysis. CHIP-GLAS is a novel high-throughput technique with combination of chromatin precipitation and oligonucleotide-based microarray. This technology will allow us to identify the genome-wide downstream target genes directly bound by TBX3 in hES cells.
We expect that the proposed experiments will identify a key regulator for hES cell differentiation and open a new avenue to understanding the function of TBX3 in hES cells. The CHIP-GLAS promoter array provides us a cutting edge tool and allows us to examine the broad function of TBX3. We anticipate that the study will significantly enhance our understanding of TBX3 function in hES cell differentiation.
STUDY DESIGN NIH-approved cell lines will be available at the Sue and Bill Gross Stem Cell Research Core Facility at the University of California, Irvine. Non-NIH-approved cell lines will be obtained from Sue \& Bill Gross Stem Cell Core at UC Irvine.
Environment: Huang Lab is currently supported by the Helen and Larry Hoag Foundation and the Susan Komen Foundation. There are no active grants from the federal government. Previously, Dr. Huang was supported by K23 and R03 grants. They were completed in 2004 and 2006, respectively. No equipment was purchased with the funds from the federal grants. As all equipment currently in Huang lab was purchased with the UCI startup fund or with private funds, there is no conflict with government regulations.
At University California, Irvine, Sue and Bill Gross Stem Cell Research Center will be a key component of the Stem Cell Core Facility. This facility provides stem cell technology and resources to the UCI faculty (Please see attached letter). By merging technical and scientific expertise in a number of essential disciplines, the Core harbors a diverse tool kit for the exploration of multiple aspects of stem cell biology. The Core also provides a knowledge base for differentiating, genetically modifying and assaying human embryonic stem cells (hESCs) in support of multiple stem cell projects on campus and in the surrounding area. All services and procedures are performed in accordance with good quality assurance and record keeping practices pursuant to standard operating procedures and good laboratory practices.
The Sue and Bill Gross Stem Cell Research Center The human embryonic stem (hES) cell core facility of the Sue and Bill Gross Stem Cell Research Center opened in April 2006. It occupies approximately 10,000 square feet of space in the research park immediately adjacent to the University of California, Irvine campus. Approximately $1.7 million were committed by the UCI to fully equip the facility for all aspects on hES cell research. Further gifts totaling $236,687 from the Fuji Foundation and the Nichols Foundation provided additional major equipment and supplies that are available for all investigators. The facility was set up as a Federal-free zone in which investigators can to carry out all aspects of hES cell research. Individual rooms are equipped with tissue culture biosafety cabinets, CO2 incubators, an inverted microscope, a dissecting microscope, digital imaging equipment, a centrifuge, a water bath and a dedicated refrigerator and freezer. Ten such tissue culture set-ups as well as standard lab bench space are available to UCI investigators and visitors.
The facility also has major pieces of equipment needed for hES cell analysis such as a Zeiss 510 Meta Two-Photon Confocal Microscope. The facility will shortly have a BD LSR II Flow cytometer and a BD FacsAria cell sorter. Pretested reagents will be available to investigators through the core facility. These will include medium components, growth factors, feeder cells, gelatin, Matrigel, antibodies and primers to assay stem cell marker expression. In addition, the core facility will assist in karyotype analysis and tumor formation tests of hES cells.
Study design
- Observational model
- Case only
- Time perspective
- Other
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- No subjects will be consented for this study. Approximately 2 to 4 cell lines will be collected.
Key inclusion criteria (1 listed)
- none
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The cell morphology and biochemical changes will be examined for the effects of TBX3 knockdown on hES cell differentiation, including testing human ß-CG estradiol and progesterone.
Time frame: 3 years
To identify the targets of TBX3 in BMP4-induced hES cells, we will perform ChIP-GLAS analysis. CHIP-GLAS will allow us to identify the genome-wide downstream target genes directly bound by TBX3 in hES cells.
Time frame: 3 years
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2021.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of TBX3 and Cell Differentiation, run by University of California, Irvine.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The cell morphology and biochemical changes will be examined for the effects of TBX3 knockdown on hES cell differentiation, including testing human ß-CG estradiol and progesterone. (time frame: 3 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.